A pre-specified cost-utility analysis tied to the phase III CHALLENGE trial found that a 3-year structured exercise program (SEP) delivered both lower total costs and higher effectiveness versus health education materials (HEM) for patients with resected stage III or high-risk stage II colon cancer. Results were scheduled for presentation at the 2026 ASCO Annual Meeting. The analysis used a Canadian public payer perspective over a 5-year time horizon, reporting that SEP was dominant over HEM, with lower costs (–$179) and small gains in life-years (+0.06) and quality-adjusted life-years (+0.10). The incremental value held in a majority of bootstrap samples and largely met common willingness-to-pay thresholds. Major cost drivers included recurrence/new malignancy and anticancer therapy, with scenario analyses reinforcing the base case. Over a 10-year horizon, the program showed cost savings and additional life-years gained, and the societal perspective met typical cost-effectiveness thresholds. For biotech and clinical stakeholders, the update matters because non-drug interventions increasingly need evidence that they can support value-based care—especially when bundled with oncology pathways.